Preclinical Development – Biomolecular
2019 PharmSci 360
Bispecific T cell engagers (bs-TCE) are a promising class of immune-oncology agents in targeted cancer immunotherapy. Classical bs-TCE designs consist of a tumor antigen-binding domain combined with a binding domain against the CD3 T-cell receptor-signaling complex. CD3-based bs-TCE development is encountering challenges, which in part are explained by the fact that they activate all T-cells irrespective of lineage, which may lead to exaggerated T cell activation and cytokine release in some patients and limited efficacy due to T suppressor cell activation in others. The optimization of bs-TCEs design and development to increase tumor selectivity and widen the therapeutic window therefore is of high interest to maximise their therapeutic potential.